A5037724832- Nutrition and Health in Aging
- Cystic Fibrosis Research Advances
- GDF15 and Related Biomarkers
- Folate and B Vitamins Research
- Histone Deacetylase Inhibitors Research
- Muscle Physiology and Disorders
- Childhood Cancer Survivors' Quality of Life
- Frailty in Older Adults
- Cardiac electrophysiology and arrhythmias
- Pain Mechanisms and Treatments
- Pesticide Residue Analysis and Safety
- Acute Lymphoblastic Leukemia research
- Anomaly Detection Techniques and Applications
- Ion Channels and Receptors
- Botulinum Toxin and Related Neurological Disorders
- Analytical Methods in Pharmaceuticals
- Single-cell and spatial transcriptomics
- Body Composition Measurement Techniques
- Cell Image Analysis Techniques
- ECG Monitoring and Analysis
- Pain Management and Treatment
- Herbal Medicine Research Studies
- AI in cancer detection
- Cancer Risks and Factors
Pfizer (United Kingdom)
2010-2024
Edinburgh Cancer Research
2024
Duke Medical Center
2024
Zimmer Biomet (United Kingdom)
2024
Pfizer (United States)
2008-2020
Pfizer (Belgium)
2014
Cachexia is a common complication of cancer and associated with an increased risk death. The level growth differentiation factor 15 (GDF-15), circulating cytokine, elevated in cachexia. In small, open-label, phase 1b study involving patients cachexia, ponsegromab, humanized monoclonal antibody inhibiting GDF-15, was improved weight, appetite, physical activity, along suppressed serum GDF-15 levels.
The effect of PF-05089771, a selective, peripherally restricted Nav1.7 sodium channel blocker on pain due to diabetic peripheral neuropathy was investigated in randomised, placebo and active-controlled parallel group clinical trial (NCT02215252). A 1-week placebo-run the period followed by 4-week treatment run-out/taper-down period. Single-blind administered throughout run-in run-out periods. Subjects were randomised receive either PF-05089771 150 mg twice daily, pregabalin or during One...
Abstract Purpose: Cachexia is common in patients with advanced cancer and associated elevated serum growth differentiation factor 15 (GDF-15) concentrations. This first-in-patient (phase Ib), 24-week study assessed use of ponsegromab, a mAb against GDF-15, adults cancer, cachexia, GDF-15 concentration. Patients Methods: Participants (n = 10) received open-label ponsegromab subcutaneous 200 mg every 3 weeks for 12 addition to standard-of-care anticancer treatment. Ponsegromab safety,...
Cancer cachexia is a multifactorial metabolic wasting syndrome characterized by anorexia, unintentional loss of weight involving both skeletal muscle and adipose tissues, progressive functional impairment reduced survival. Therapeutic strategies for this serious condition are very limited. Growth differentiation factor 15 (GDF-15) cytokine that implicated in cancer may represent biomarker potential therapeutic target. Ponsegromab potent selective humanized monoclonal antibody inhibits...
The transient receptor potential (subfamily M, member 8; TRPM8) is a nonselective cation channel localized in primary sensory neurons, and candidate for cold thermosensing, mediation of pain, bladder overactivity. Studies with TRPM8 knockout mice selective blockers demonstrate lack sensitivity reduced pain various rodent models. Furthermore, significantly lower body temperature. We have identified moderately potent (IC<sub>50</sub> = 103 nM), antagonist, PF-05105679...
Abstract Background: Cachexia is common in patients with advanced cancer and has been associated elevated serum growth/differentiation factor 15 (GDF-15) concentrations. This first-in-patient, phase 1b, study assessed the use of ponsegromab, a monoclonal antibody against GDF-15, participants cachexia. Methods: Adult (n = 10) cachexia, (non-small cell lung, colorectal, or pancreatic), concentrations GDF-15 received open-label subcutaneous ponsegromab every three weeks (Q3W) for 12 addition to...
Historically, histopathology evaluation is performed by a pathologist generating qualitative assessment on thin tissue sections glass slides. In the past decade, there has been growing interest for tools able to reduce human subjectivity and improve workload. Whole slide scanning technology combined with object orientated image analysis can offer capacity of fast reliable results. present study, we use these emerging technologies characterise mouse model chronic asthma. We monitored...
<div>AbstractPurpose:<p>Cachexia is common in patients with advanced cancer and associated elevated serum growth differentiation factor 15 (GDF-15) concentrations. This first-in-patient (phase Ib), 24-week study assessed use of ponsegromab, a mAb against GDF-15, adults cancer, cachexia, GDF-15 concentration.</p>Patients Methods:<p>Participants (<i>n</i> = 10) received open-label ponsegromab subcutaneous 200 mg every 3 weeks for 12 addition to...
<p>Study design</p>
<p>Summary of accelerometry-based monitoring sedentary activity time (A), light (B), moderate (C), average level during the maximum 6 minutes daily (D), total sleep (E), and gait speed (F) at baseline, week 12</p>
<p>Participant disposition</p>
<p>Summary of supplementary methods</p>
<p>Median serum unbound and total ponsegromab GDF-15 concentration–time profiles (semi-log scale)</p>
<p>Summary of accelerometry-based monitoring sedentary activity time (A), light (B), moderate (C), average level during the maximum 6 minutes daily (D), total sleep (E), and gait speed (F) at baseline, week 12</p>
<p>Median serum unbound and total ponsegromab GDF-15 concentration–time profiles (semi-log scale)</p>
<p>Summary of supplementary methods</p>
<div>AbstractPurpose:<p>Cachexia is common in patients with advanced cancer and associated elevated serum growth differentiation factor 15 (GDF-15) concentrations. This first-in-patient (phase Ib), 24-week study assessed use of ponsegromab, a mAb against GDF-15, adults cancer, cachexia, GDF-15 concentration.</p>Patients Methods:<p>Participants (<i>n</i> = 10) received open-label ponsegromab subcutaneous 200 mg every 3 weeks for 12 addition to...